Technavio forecasts that the Amyotrophic Lateral Sclerosis (ALS) Treatment Market will expand by USD 663.7 million, with a CAGR of 12.79% from 2023 to 2028. ALS is a severe neurodegenerative disease that affects motor neurons, causing symptoms like difficulty breathing, swallowing, and speaking. The market is fueled by the growing number of ALS patients, the significant gap in available treatment options, and rising investments in research for neurodegenerative disorders. As the aging population increases, the need for ALS treatments to combat both sporadic and familial cases becomes even more pressing. The market also benefits from the development of innovative drugs targeting the disease's underlying causes, including gene mutations and glutamate toxicity. ALS treatments, often delivered through hospital pharmacies, are expected to gain traction as more effective solutions emerge in the coming years.

Click here to download Amyotrophic Lateral Sclerosis (ALS) Treatment Market Sample PDF Click here to Contact us for more Information